A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.

MLA

Duska, Linda R., et al. “A Window-of-Opportunity Clinical Trial of Dasatinib in Women with Newly Diagnosed Endometrial Cancer.” Cancer Chemotherapy and Pharmacology, vol. 83, no. 3, Mar. 2019, pp. 473–82. EBSCOhost, https://doi.org/10.1007/s00280-018-3749-7.

APA

Duska, L. R., Petroni, G. R., Lothamer, H., Faust, W., Jr, Beumer, J. H., Christner, S. M., Mills, A. M., Fracasso, P. M., & Parsons, S. J. (2019). A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. Cancer Chemotherapy and Pharmacology, 83(3), 473–482. https://doi.org/10.1007/s00280-018-3749-7

Chicago

Duska, Linda R, Gina R Petroni, Heather Lothamer, William Faust Jr, Jan H Beumer, Susan M Christner, Anne M Mills, Paula M Fracasso, and Sarah J Parsons. 2019. “A Window-of-Opportunity Clinical Trial of Dasatinib in Women with Newly Diagnosed Endometrial Cancer.” Cancer Chemotherapy and Pharmacology 83 (3): 473–82. doi:10.1007/s00280-018-3749-7.